Human Anti-EGFR Recombinant Antibody (clone MR1) (CAT#: PABC-040)

Figure 1 Epidermal growth factor receptor variant III (EGFRvIII) recognition by different antibodies.

(A) Lysates of EGFRvIII-transfected and parental A431 and HEK293T cells were analyzed by immunoblot using the stated antibodies for detection and b-actin as a loading control. Arrows indicate the expected molecular weights of wild-type (wt) EGFR and EGFRvIII, which appears as a double band. 13.1.2 exclusively detected EGFRvIII, whereas ch806 and MR1-1 also bound to wt EGFR on nontransfected cells. (B) Indirect immunofluorescence revealed a similar binding of EGFRvIII antibodies to EGFRvIII-expressing A431 (A431-vIII) and HEK293T (HEK293T-vIII) cells (lower panel). Additional binding to A431 cells was obtained with MR1-1 (grey line) and ch806 (black line). MR1-1 also displayed reactivity with HEK293T cells, whereas 13.1.2 (dotted line) only bound to EGFRvIIItransfected cells. Zalutumumab (black fill) recognized wt EGFR and EGFRvIII. An irrelevant IgG1 antibody (KLH) served as a control (grey fill).

Klausz, K. , Berger, S. , Bueren, J. J. L. V. , Derer, S. , Lohse, S. , & Dechant, M. , et al. (2011). Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (egfr) and its variant iii (egfrviii). Cancer Science, 102(10), 1761-1768.